3 – Eisai Withdraws Application for Ultra-High Dose of Mecobalamin, a B12 Form, as ALS Treatment
Eisai announced it has withdrawn its new drug application for an ultra-high dose Mecobalamin as a treatment for amyotrophic lateral sclerosis (ALS) in Japan, and is reviewing its next steps in consultation with Japanese regulatory officials.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?